<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915718</url>
  </required_header>
  <id_info>
    <org_study_id>XCheng</org_study_id>
    <nct_id>NCT02915718</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy</brief_title>
  <official_title>A Randomized, Open, Controlled Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dilated cardiomyopathy (DCM) causes significant morbidity and mortality and is the third most
      common cause of heart failure and the most frequent reason for heart transplantation. The
      etiology of dilated cardiomyopathy(DCM) is complex. There is a growing body of literature
      suggesting that the humoral immune system activation and autoantibodies against myocardial
      generation play an important role in the progression of DCM. At present immunoadsorption
      technology has been successfully applied in autoimmune antibody removal treatment of a
      variety of diseases. And some applications of immunoadsorption(IA) in patients with DCM
      showed that immunoadsorption(IA) can indeed reduce the autoantibodies, improve symptoms and
      prognosis, but additional research is needed to identify indications and instruments for the
      IA treatment of DCM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients randomly divided into 2 groups： experimental group and control group

      experimental group：

      Device: protein A immunoadsorption

      protein-A immunoadsorption for 5 days and i.v.(intravenous injection) IgG(Immunoglobulin
      G）（0.5g/kg Body weight） substitution

      control group：

      non intervention
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) at rest</measure>
    <time_frame>six months</time_frame>
    <description>determined by contrast echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVEF at rest</measure>
    <time_frame>1 year</time_frame>
    <description>determined by contrast echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of brain natriuretic peptides (BNP) or N-terminal pro-Brain Natriuretic Peptide(NT pro-BNP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>protein A immunoadsorption for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>non intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>protein A immunoadsorption</intervention_name>
    <description>protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>plasma adsorption</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dilated cardiomyopathy

          -  LVEF &lt;= 40% determined by contrast echocardiography

          -  NYHA(New York Heart Association) class II - IV

          -  Age 18-70

          -  Disease duration: symptomatic heart failure ≥ 6 months prior to screening date

          -  Treatment with Angiotensin-Converting Enzyme inhibitors(ACEI) or angiotensin II
             receptor blockers (ARB), beta-blockers, and aldosterone antagonists (the latter at the
             discretion of the attending physician), for at least 6 months and at stable doses for
             at least 2 months prior to screening date.

          -  β1 adrenergic receptor antibody positive

          -  The patient's informed consent

        Exclusion Criteria:

          -  NYHA class IV patients who are bed-ridden and dependent upon parenteral medication

          -  Cardiac insufficiency resulting from another basic disease (e.g. coronary artery
             disease, ≥50% stenosis of major vessel as ascertained by coronary angiography
             performed more recent than three years before screening date, hypertensive heart
             disease, or valvular defects &gt;second degree

          -  History of myocardial infarction

          -  Acute myocarditis according to Dallas criteria

          -  Endocrine disorder excluding insulin-dependent diabetes mellitus

          -  Implanted cardiac defibrillator (ICD) &lt;1 month before screening date

          -  Cardiac resynchronization therapy (CRT) &lt;6 months before screening date

          -  I.v. medication with inotropic drugs, vasodilators or repeated (&gt;1/day) i.v.
             administration of diuretics.

          -  Active infectious disease, or signs of ongoing infection with C-reactive protein(CRP)
             &gt;10mmol/L

          -  Impaired renal function (serum creatinine &gt;220 µmol/L)

          -  Any disease requiring immunosuppressive drugs

          -  Anaemia (haemoglobin below 90 g/L) due to other causes than congestive heart
             failure(CHF)

          -  Pregnancy or lactation, or childbearing potential without appropriate contraception

          -  Alcohol or drug abuse

          -  Presence of a malignant tumour, or remission of malignancy &lt; 5 years

          -  Refusal of the patient to provide consent

          -  Suspected poor capability to follow instructions and cooperate

          -  Another life-threatening disease with poor prognosis (survival less than 2 years)

          -  Participation in any other clinical study within less than 30 days prior to screening
             date

          -  Previous treatments with IA or immunoglobulin

          -  Contraindications for application of the echocardiography contrast agent used (in
             accordance to the product specification).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tian Xie, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Cheng, doctor</last_name>
    <phone>+8615972150162</phone>
    <email>715494934@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tian Xie, master</last_name>
      <phone>+8615972150162</phone>
      <email>715494934@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ameling S, Herda LR, Hammer E, Steil L, Teumer A, Trimpert C, Dörr M, Kroemer HK, Klingel K, Kandolf R, Völker U, Felix SB. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J. 2013 Mar;34(9):666-75. doi: 10.1093/eurheartj/ehs330. Epub 2012 Oct 25.</citation>
    <PMID>23100283</PMID>
  </results_reference>
  <results_reference>
    <citation>Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail. 2012 Dec;14(12):1374-88. doi: 10.1093/eurjhf/hfs123. Epub 2012 Aug 14.</citation>
    <PMID>22892122</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>October 8, 2016</last_update_submitted>
  <last_update_submitted_qc>October 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiang Cheng</investigator_full_name>
    <investigator_title>Professor, Chief Physician, Deputy Director</investigator_title>
  </responsible_party>
  <keyword>dilated cardiomyopathy</keyword>
  <keyword>immunoadsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

